Reprogramming the Genome: Applications of CRISPR-Cas in Non-mammalian Systems, Part A presents a collation of chapters written by global, eminent scientists. CRISPR-Cas9 system is an RNA-mediated immune system of bacteria and archaea that protects from bacteriophage infections. It is one of the revolutionized technologies to uplift biology to the next stages. Chapters in this release include An Introduction and applications of CRISPR-Cas Systems, History, evolution and classification of CRISPR-Cas associated systems, CRISPR based bacterial genome editing and removal of pathogens, CRISPR based genome editing and removal of human viruses, CRISPR based development of RNA editing and diagnostic platform, and much more.
Additional sections cover Genome engineering in insects for control of vector borne diseases, Development of insect cell line using CRISPR technology, CRISPRing protozoan parasites to better understand the biology of diseases, CRISPR based genome editing of Caenorhabditis elegans, and a variety of other important topics.
- Offers a basic understanding and clear picture of genome editing CRISPR-Cas systems in different organisms
- Explains how to create an animal model for disease diagnosis/research and reprogram CRISPR for removal of virus, bacteria, fungi, protozoan, and many more
- Discusses the advances, patents, applications, challenges and opportunities in CRISPR-Cas9 systems in basic sciences, biomedicine, virology, bacteriology, molecular biology, and many more
| Contributors |
|
ix | |
| Preface |
|
xi | |
|
1 An introduction and use of the CRISPR-Cas systems |
|
|
1 | (10) |
|
|
|
|
|
1 | (1) |
|
2 History and mechanism of action of CRISPR-Cas systems |
|
|
2 | (1) |
|
3 Progress and use of the CRISPR-Cas systems |
|
|
2 | (5) |
|
4 Conclusion and future remarks |
|
|
7 | (4) |
|
|
|
8 | (1) |
|
|
|
8 | (3) |
|
2 History, evolution and classification of CRISPR-Cas associated systems |
|
|
11 | (66) |
|
|
|
|
|
|
|
12 | (1) |
|
|
|
13 | (26) |
|
3 Evolution of type II CRISPR-Cas9 system as a robust gene silencing tool |
|
|
39 | (3) |
|
4 Recent advances in understanding the CRISPR-Cas systems |
|
|
42 | (19) |
|
5 Classification and evolution of CASSs |
|
|
61 | (8) |
|
|
|
69 | (8) |
|
|
|
70 | (1) |
|
|
|
70 | (7) |
|
3 CRISPR based bacterial genome editing and removal of pathogens |
|
|
77 | (16) |
|
|
|
|
|
|
|
|
|
Shunmugiah Karutha Pandian |
|
|
|
|
|
|
78 | (1) |
|
2 Discovery of CRISPR/Cas9 system |
|
|
79 | (1) |
|
3 CRISPR/Cas9: A bacterial adaptive immune mechanism |
|
|
80 | (1) |
|
4 Other components in CRISPR/Cas system |
|
|
80 | (1) |
|
5 Mechanism of action of gene editing using CRISPR/Cas9 system |
|
|
81 | (3) |
|
6 Strategy of genome editing in bacteria |
|
|
84 | (2) |
|
7 Gene editing in beneficial bacteria |
|
|
86 | (1) |
|
8 Removal of pathogenic bacteria |
|
|
86 | (1) |
|
9 Advantages and disadvantages of CRISPR/Cas9 system |
|
|
87 | (1) |
|
10 Ethical implication of CRISPR/Cas9 |
|
|
88 | (1) |
|
|
|
89 | (4) |
|
|
|
89 | (1) |
|
|
|
90 | (3) |
|
4 CRISPR based genome editing and removal of human viruses |
|
|
93 | (24) |
|
|
|
|
|
94 | (3) |
|
2 CRISPR based genome editing of human viruses |
|
|
97 | (3) |
|
3 Advantages and challenges of genome editing of human viruses based on CRISPR |
|
|
100 | (1) |
|
4 CRISPR based removal of human viruses |
|
|
101 | (7) |
|
5 Perspectives and limitations of removal of human viruses based on CRISPR |
|
|
108 | (3) |
|
6 Conclusion and future remark |
|
|
111 | (6) |
|
|
|
112 | (5) |
|
5 CRISPR based development of RNA editing and the diagnostic platform |
|
|
117 | (44) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shunmugiah Karutha Pandian |
|
|
|
|
|
|
|
|
|
|
118 | (2) |
|
2 Recent updates in CRISPR-Cas9 technology |
|
|
120 | (1) |
|
3 Comparison of ZFN, TALEN and CRISPR-Cas9 platforms |
|
|
121 | (5) |
|
4 Molecular mechanism of CRISPR-based RNA editing |
|
|
126 | (1) |
|
5 CRISPR-Cas-based biosensors/biosensing devices |
|
|
127 | (7) |
|
6 Mechanism of CRISPR-based diagnostic tool |
|
|
134 | (4) |
|
7 Types of CRISPR-based diagnostic methods |
|
|
138 | (14) |
|
8 Conclusions and future directions |
|
|
152 | (9) |
|
|
|
154 | (7) |
|
6 CRISPR-based pathogenic fungal genome editing for control of infection and disease |
|
|
161 | (36) |
|
|
|
|
|
162 | (3) |
|
2 Genome editing in plant pathogenic fungi and fungus-like oomycetes |
|
|
165 | (13) |
|
3 Genome editing in human and animal pathogenic fungi |
|
|
178 | (10) |
|
4 Conclusion and future perspective |
|
|
188 | (7) |
|
|
|
189 | (6) |
|
|
|
195 | (2) |
|
7 Genome engineering in insects for the control of vector borne diseases |
|
|
197 | (28) |
|
|
|
|
|
|
|
198 | (2) |
|
|
|
200 | (2) |
|
|
|
202 | (2) |
|
|
|
204 | (4) |
|
5 Application of genome engineering to control vector insects |
|
|
208 | (7) |
|
|
|
215 | (3) |
|
7 Conclusion and future prospects |
|
|
218 | (7) |
|
|
|
218 | (7) |
| Index |
|
225 | |
Dr Vijai Singh is a Professor and Dean (Research & Innovation) at School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. He was an Associate Professor in the Department of Biosciences, School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. Prior this this, he was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, India and also an Assistant Professor in the Department of Biotechnology at the Invertis University, Bareilly, India. Prior to that, he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He received his Ph.D. in Biotechnology from the National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on building novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally, his laboratory is working on CRISPR-Cas9 tools for genome editing. He has more than 11 years of research and teaching experience in synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has published 100 articles, 70 chapters, 15 books and 3 patents. He serves as an associate editor, editorial board member, and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.
